NuVasive (NuVasive) Additional Paid-In Capital : $1,488 Mil(As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NuVasive Additional Paid-In Capital?

NuVasive's quarterly additional paid-in capital increased from Dec. 2022 ($1,469 Mil) to Mar. 2023 ($1,476 Mil) and increased from Mar. 2023 ($1,476 Mil) to Jun. 2023 ($1,488 Mil).

NuVasive's annual additional paid-in capital declined from Dec. 2020 ($1,550 Mil) to Dec. 2021 ($1,435 Mil) but then increased from Dec. 2021 ($1,435 Mil) to Dec. 2022 ($1,469 Mil).

NuVasive Additional Paid-In Capital Historical Data

The historical data trend for NuVasive's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Additional Paid-In Capital Chart

NuVasive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

1,397.83

1,429.85

1,550.00

1,434.98

1,469.41

NuVasive Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															1,453.01	1,457.83	1,469.41	1,476.32	1,487.70

NuVasive Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

NuVasive Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NuVasive's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NuVasive (NuVasive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

12101 Airport Way, Broomfield, CO, USA, 92121

Website

https://www.nuvasive.com

NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.

Executives

Michael Farrington	officer: SVP, People and Culture	7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry	director, officer: Chief Executive Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton	officer: SVP, CHRO	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo	director	ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale	officer: Chief Human Resources Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore	officer: EVP, Global Business Units	7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher	officer: EVP, Global Commercial	14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link	officer: Exec. VP U.S. Sales	7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh	officer: EVP and CFO	675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf	officer: SVP, Global Operations	7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock	officer: President, U.S. Commercial	7475 LUSK BLVD, SAN DIEGO CA 92121